Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Nuravax, Inc. · with National Institute on Aging (NIA), Institute for Molecular Medicine · NCT07142278

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 40–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
24
US sites recruiting
1
Study start
September 25, 2026
Record last updated
September 30, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.

Being studied: DUVAX 200 µg; DUVAX 400 µg; Placebo (Adjuvant only)

Conditions: Alzheimer Disease; Alzheimer Disease (AD); Preclinical Alzheimer's Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Healthy males and non-pregnant, non-lactating females, 40-65 years old
  • BMI between 18.0 and 32.0 kg/m²
  • Medically healthy with no significant abnormalities in medical history, exam, labs, ECG, or MRI
  • Signed informed consent
  • Women of childbearing potential: negative pregnancy test and use of effective contraception
  • Men: vasectomized or agree to use condoms / not donate sperm during the study period

Exclusion Criteria

  • Clinically significant medical or psychiatric illness that may affect safety or study results
  • MRI abnormalities (e.g., infarcts, microbleeds, ARIA-E) or contraindications to MRI
  • Significant lab abnormalities (e.g., liver, kidney, hematology) or positive HIV/HBV/HCV tests
  • Uncontrolled blood pressure, abnormal heart rate, or prolonged QTc interval
  • Recent serious illness, surgery, or investigational drug use within 30 days
  • Prior amyloid-beta or tau immunotherapy within 1 year
  • Use of immunosuppressive agents or chronic anticoagulants
  • History of severe vaccine reactions, autoimmune disease, or significant allergies

Recruiting US locations

  • Palm Springs Community Health Center

    Miami Lakes, FL 33014

    Site contact: Mailin Perez · 786-334-6675 · mperez@palmspringschc.com

All vaccine studies in Florida →
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta… (NCT07142278) | Bored Studies